A class action lawsuit has been filed against Insulet Corporation by investors who bought shares between February 2025 and May 2026. The suit alleges Insulet misled investors by failing to disclose defects in its manufacturing controls that posed safety risks and led to voluntary recalls of its insulin delivery products. Following these disclosures in March and May 2026, Insulet's stock price dropped significantly. Investors may be eligible to join the lawsuit, which seeks to hold the company accountable for the alleged misinformation and resulting losses.
The Taiwan Freedom Project has released a special 32-page section in The Washington Times titled "Why Taiwan Matters, Now More Than Ever," emphasizing Taiwan's critical geopolitical role and the threats it faces from China. The publication features b...
The Québec Superior Court has approved a restructuring transaction for Premier Health of America Inc., allowing the company to continue uninterrupted operations. The deal involves the acquisition of three affiliates by Polar Valley Investments Limite...
North American Niobium and Critical Minerals Corp. announced initial drill results from its Seigneurie project in Québec, confirming the presence of rare earth and niobium mineralization. Hole SGN-2026-007 returned modest grades of 76.7 ppm dysprosiu...
Bitcoin surged above $62,000 in early July, triggering over $100 million in liquidations of short positions as traders betting against the rise were forced to cover. This sharp rally was fueled by weaker-than-expected US jobs data, which shifted mark...
Solana's network usage hit a record high with 3.77 billion non-vote transactions in June 2026, driving the SOL token price above $80. This surge reflects growing adoption and on-chain activity, suggesting a favorable environment for further price gai...
